Overview

• Celltrion USA will acquire the facility from Eli Lilly for 460 billion won (about US$330 million), with closing targeted by year-end.
• The company plans 700 billion won of investment for the site including the purchase, plus up to an additional 700 billion won to expand capacity.
• The Branchburg, New Jersey drug‑substance plant is FDA‑approved, cGMP‑compliant, and has produced treatments for cancer and autoimmune diseases.
• Chairman Seo Jung-jin said the acquisition fundamentally eliminates U.S. tariff risks, following tariff threats on imported drugs that have been described as potentially reaching 250 percent.
• Celltrion says the deal establishes a one‑stop U.S. supply chain from production to commercialization, complementing earlier steps such as preemptively shipping two years of inventory and expanding local CMO arrangements.